Time to Consider HPV Vaccination after Allogeneic Stem Cell Transplantation

Citations of this article
Mendeley users who have this article in their library.


Squamous cell carcinoma (SCC) is among the most common secondary cancers after allogeneic stem cell transplantation (allo-SCT). Several types of human papillomavirus (HPV) are causally linked with SCC of the genital tract and head and neck, and the incidence of these cancers is higher among immunosuppressed patients compared to immunocompetent patients. In June 2006, a quadrivalent HPV vaccine was approved by the Food and Drug Administration (FDA) for females aged 9 to 26 years to prevent cervical warts and vulvar, vaginal, and cervical cancer. FDA approval was granted in October 2009 for males aged 9 to 26 years to prevent genital warts. The quadrivalent HPV vaccine is now available for off-label use, and may be beneficial to patients after allo-SCT. It is time to evaluate the immunogenicity and efficacy in preventing HPV-related squamous cell carcinoma in this population. © 2010.




Tedeschi, S. K., Savani, B. N., Jagasia, M., Engelhardt, B., Anasetti, C., Barrett, A. J., & Lee, S. (2010, August). Time to Consider HPV Vaccination after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 16(8), 1033–1036. https://doi.org/10.1016/j.bbmt.2010.03.007

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free